Market Place
Sourcing Support
CG Oncology Updates PIVOT-006 Phase 3 for Topline Data
09 Jan 2026 //
GLOBENEWSWIRE
CG Oncology To Present At J.P. Morgan Healthcare Conference
06 Jan 2026 //
GLOBENEWSWIRE
SUO-CTC and CG Oncology Announce the 2nd Annual NMIBC Fellowship
18 Dec 2025 //
GLOBENEWSWIRE
Cretostimogene Grenadenorepvec Shows Potential As Key Therapy
05 Dec 2025 //
GLOBENEWSWIRE
CG Oncology To Unveil Cretostimogene Grenadenorepvec Data At SUO
25 Nov 2025 //
GLOBENEWSWIRE
CG Oncology Shows Durable Tolerability in BOND-003 Cohort C trial
05 Sep 2025 //
GLOBENEWSWIRE
CG Oncology Completes Enrollment in PIVOT-006
03 Sep 2025 //
GLOBENEWSWIRE
CG Oncology Q2 2025 Financial Results and Business Updates
08 Aug 2025 //
GLOBENEWSWIRE
CG Oncology Announces Durability Data in BOND-003 at AUA
26 Apr 2025 //
GLOBENEWSWIRE
CG Oncology Reports 2024 Financial Results and Business Updates
28 Mar 2025 //
GLOBENEWSWIRE
Cretostimogene Grenadenorepvec Data Shows Best Durability, Safety
24 Mar 2025 //
GLOBENEWSWIRE
SUO-CTC & CG Oncology Launch NMIBC Research Fellowship Award
06 Dec 2024 //
GLOBENEWSWIRE
CG Oncology To Present Cretostimogene Grenadenorepvec Results At SUO
20 Nov 2024 //
GLOBENEWSWIRE
CG Oncology Publishes Cretostimogene Data in Nature Medicine
11 Nov 2024 //
GLOBENEWSWIRE
CG Oncology Initiates Expanded Access Program For Cretostimogene Grenadenorepvec
18 Jun 2024 //
GLOBENEWSWIRE
CG Oncology Announces Publication Of CORE-001 Study In Nature Medicine
06 Jun 2024 //
GLOBENEWSWIRE
Cg Bcel-Core-001 Full Results: Cretostimogene + Pembro Positive At Asco24
24 May 2024 //
GLOBENEWSWIRE
CG Oncology sets new bar in bladder cancer, months after huge IPO
04 May 2024 //
FIERCE BIOTECH
Cretostimogene Shows 75.2% Response In Bladder Cancer
03 May 2024 //
GLOBENEWSWIRE
CG Oncology Unveils Cretostimogene+Pembrolizumab Results at ASCO 2024
24 Apr 2024 //
GLOBENEWSWIRE
CG Oncology Announces First Patient Dosed in Phase 3 Trial of Cretostimogene
27 Feb 2024 //
GLOBENEWSWIRE
CG Oncology brings in $380M from first biotech IPO of 2023
25 Jan 2024 //
FIERCE BIOTECH
Biotech`s 2024 IPO season kicks off with heavy demand for CG Oncology
24 Jan 2024 //
ENDPTS
CG Oncology aims for $209M IPO, as more biotechs eye Nasdaq
18 Jan 2024 //
FIERCE BIOTECH
CG Oncology plans IPO ahead of phase 3 bladder cancer readout
03 Jan 2024 //
FIERCE BIOTECH
CG Oncology files for IPO as biotech market shows signs of a rebound
02 Jan 2024 //
ENDPTS
CG Oncology Receives Fast Track and Breakthrough Designation for Cretostimogene
05 Dec 2023 //
BUSINESSWIRE
CG Oncology Announces Presentation of Data for Cretostimogene Grenadenorepvec
14 Nov 2023 //
BUSINESSWIRE
CG Oncology Announces $105 Million Oversubscribed Crossover Financing
02 Aug 2023 //
BUSINESSWIRE
CG raises $105M crossover round to fund phase 3 cancer trial
02 Aug 2023 //
FIERCE BIOTECH
CG Oncology Announces New Ph2 Data with Cretostimogene Grenadenorepvec (CG0070)
01 May 2023 //
BUSINESSWIRE
Phase 2 Data With CG0070 in Combination with KEYTRUDA in BCG-Unresponsive NMIBC
10 Apr 2023 //
BUSINESSWIRE
